STRATA Skin Sciences Files 8-K with Material Agreement
Ticker: SSKN · Form: 8-K · Filed: Sep 3, 2025 · CIK: 1051514
| Field | Detail |
|---|---|
| Company | Strata Skin Sciences, Inc. (SSKN) |
| Form Type | 8-K |
| Filed Date | Sep 3, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $2.204, $2.4 m, $50,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, 8-K, corporate-actions
TL;DR
STRATA Skin Sciences signed a new material agreement, filing an 8-K today.
AI Summary
On September 2, 2025, STRATA Skin Sciences, Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes Regulation FD disclosures and financial statements/exhibits. The company was formerly known as MELA SCIENCES, INC. and ELECTRO OPTICAL SCIENCES INC.
Why It Matters
This 8-K filing indicates a significant new agreement for STRATA Skin Sciences, which could impact its business operations and financial performance.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities that are not yet fully understood.
Key Players & Entities
- STRATA Skin Sciences, Inc. (company) — Registrant
- MELA SCIENCES, INC. (company) — Former Company Name
- ELECTRO OPTICAL SCIENCES INC (company) — Former Company Name
- September 2, 2025 (date) — Earliest event reported
- September 3, 2025 (date) — Filing Date
FAQ
What is the nature of the material definitive agreement filed by STRATA Skin Sciences, Inc.?
The 8-K filing indicates the entry into a material definitive agreement, but the specific details of the agreement are not provided in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on September 2, 2025.
What is the filing date of this 8-K report?
The filing date of this 8-K report is September 3, 2025.
What were STRATA Skin Sciences, Inc.'s previous names?
STRATA Skin Sciences, Inc. was formerly known as MELA SCIENCES, INC. and ELECTRO OPTICAL SCIENCES INC.
What is STRATA Skin Sciences, Inc.'s state of incorporation and fiscal year end?
STRATA Skin Sciences, Inc. is incorporated in Delaware and its fiscal year ends on December 31.
Filing Stats: 1,042 words · 4 min read · ~3 pages · Grade level 10.7 · Accepted 2025-09-03 08:20:43
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share SSKN The Nasdaq
- $2.204 — "Common Stock"), at a purchase price of $2.204 per Share. The purchase price per share
- $2.4 m — from the Offering will be approximately $2.4 million, before paying the placement agen
- $50,000 — ed to reimburse Ladenburg Thalman up to $50,000 for its expenses. Pursuant to the terms
Filing Documents
- ea0255756-8k_strata.htm (8-K) — 33KB
- ea025575601ex1-1_strata.htm (EX-1.1) — 93KB
- ea025575601ex5-1_strata.htm (EX-5.1) — 10KB
- ea025575601ex10-1_strata.htm (EX-10.1) — 175KB
- ea025575601ex99-1_strata.htm (EX-99.1) — 9KB
- ex5-1_001.jpg (GRAPHIC) — 3KB
- 0001213900-25-083709.txt ( ) — 569KB
- sskn-20250902.xsd (EX-101.SCH) — 3KB
- sskn-20250902_lab.xml (EX-101.LAB) — 33KB
- sskn-20250902_pre.xml (EX-101.PRE) — 22KB
- ea0255756-8k_strata_htm.xml (XML) — 4KB
01 Entry into
Item 1.01 Entry into a Material Definitive Agreement. On September 2, 2025, Strata Skin Sciences, Inc., a Delaware corporation (the "Company"), entered into Securities Purchase Agreements (each a "Purchase Agreement") with three institutional investor (the "Purchasers"), pursuant to which the Company agreed to issue to the Purchasers, in a registered direct offering (the "Offering"), an aggregate of 1,097,547 shares of the Company's common stock (the "Shares"), par value $0.001 per share ("Common Stock"), at a purchase price of $2.204 per Share. The purchase price per share equals the "Minimum Price," as defined in Nasdaq Listing Rule 5635(d), representing the average closing price of the Common Stock on the Nasdaq Capital Market for the five consecutive trading days immediately preceding the execution of the Purchase Agreements. The gross proceeds from the Offering will be approximately $2.4 million, before paying the placement agent fees and other estimated offering expenses. The Company intends to use the net proceeds for general corporate and working capital purposes. The Offering is being made pursuant to the shelf registration on November 22, 2024, and declared effective on December 18, 2024. The Offering is being made only by means of a base prospectus forming a part of the effective registration statement and a prospectus supplement relating to the Offering. The Offering is expected to close on or about September 4, 2025, subject to the satisfaction of customary closing conditions. In connection with the Offering, on September 2, 2025, the Company entered into a placement agency agreement (the "Placement Agency Agreement") with Ladenburg Thalmann & Co. Inc., as the sole placement agent ("Ladenburg Thalman"). In connection with the Placement Agency Agreement, the Company agreed to pay Ladenburg Thalman an aggregate cash fee o
01 Regulation
Item 7.01 Regulation FD Disclosure. On September 3, 2025, the Company issued a press release announcing the pricing of the Offering. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. 1 Item9.01 Financial (d) Exhibits. Exhibit No. Description 1.1 Placement Agency Agreement 5.1 Opinion of Stevens & Lee, P.C. 10.1 Form of the Securities Purchase Agreement. 23.1 Consent of Stevens & Lee, P.C. (contained in Exhibit 5.1) 99.1 Pricing Press Release dated September 3, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securiti es Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. STRATA SKIN SCIENCES, INC. Dated: September 3, 2025 By: /s/ Dr. Dolev Rafaeli Name: Dr. Dolev Rafaeli Title: President and Chief Executive Officer 3